{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Generalized+Epilepsy", "query": { "condition": "Primary Generalized Epilepsy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Generalized+Epilepsy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:39:04.342Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00104416", "title": "Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy, Tonic-Clonic" ], "interventions": [ { "name": "lamotrigine (LAMICTAL) extended-release", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 153, "start_date": "2004-12", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2017-01-02", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 64, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104416" }, { "nct_id": "NCT01431326", "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenovirus", "Anesthesia", "Anxiety", "Anxiolysis", "Autism", "Autistic Disorder", "Bacterial Meningitis", "Bacterial Septicemia", "Benzodiazepine", "Bipolar Disorder", "Bone and Joint Infections", "Central Nervous System Infections", "Convulsions", "Cytomegalovirus Retinitis", "Early-onset Schizophrenia Spectrum Disorders", "Epilepsy", "General Anesthesia", "Gynecologic Infections", "Herpes Simplex Virus", "Infantile Hemangioma", "Infection", "Inflammation", "Inflammatory Conditions", "Intra-abdominal Infections", "Lower Respiratory Tract Infections", "Migraines", "Pain", "Pneumonia", "Schizophrenia", "Sedation", "Seizures", "Skeletal Muscle Spasms", "Skin and Skin-structure Infections", "Treatment-resistant Schizophrenia", "Urinary Tract Infections", "Withdrawal", "Sepsis", "Gram-negative Infection", "Bradycardia", "Cardiac Arrest", "Cardiac Arrhythmia", "Staphylococcal Infections", "Nosocomial Pneumonia", "Neuromuscular Blockade", "Methicillin Resistant Staphylococcus Aureus", "Endocarditis", "Neutropenia", "Headache", "Fibrinolytic Bleeding", "Pulmonary Arterial Hypertension", "CMV Retinitis", "Hypertension", "Chronic Kidney Diseases", "Hyperaldosteronism", "Hypokalemia", "Heart Failure", "Hemophilia", "Heavy Menstrual Bleeding", "Insomnia" ], "interventions": [ { "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Benjamin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3520, "start_date": "2011-11", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2023-09-06", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 43, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431326" }, { "nct_id": "NCT03254680", "title": "Turmeric as Treatment in Epilepsy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Epilepsy", "Dravet Syndrome", "Lennox-Gastaut Syndrome", "Tuberous Sclerosis", "Focal Seizures" ], "interventions": [ { "name": "Turmeric", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": 0, "start_date": "2018-03", "completion_date": "2018-11", "has_results": false, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03254680" }, { "nct_id": "NCT02849626", "title": "Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Partial-Onset or Primary Generalized Tonic-Clonic Seizures" ], "interventions": [ { "name": "Perampanel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "4 Years to 12 Years" }, "enrollment_count": 180, "start_date": "2016-11-16", "completion_date": "2021-12-06", "has_results": true, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 29, "location_summary": "Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 25 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gulf Breeze", "state": "Florida" }, { "city": "Loxahatchee Groves", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02849626" }, { "nct_id": "NCT00043901", "title": "Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Epilepsy, Tonic-Clonic" ], "interventions": [ { "name": "lamotrigine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 141, "start_date": "2000-12-01", "completion_date": "2005-03-01", "has_results": false, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 80, "location_summary": "Alabaster, Alabama • Mobile, Alabama • Northport, Alabama + 71 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043901" }, { "nct_id": "NCT06051448", "title": "Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mitochondrial Diseases", "Mitochondrial Myopathies", "Mitochondrial Encephalomyopathies", "MELAS", "MERRF" ], "interventions": [ { "name": "Promoting Resilience in Stress Management (PRISM)", "type": "BEHAVIORAL" }, { "name": "Clinical-focused narrative (CFN)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-09-22", "completion_date": "2024-02-28", "has_results": false, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051448" }, { "nct_id": "NCT05147571", "title": "RNS System NAUTILUS Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy", "Idiopathic Generalized Epilepsy", "Generalized Tonic Clonic Seizure" ], "interventions": [ { "name": "Responsive stimulation", "type": "DEVICE" }, { "name": "Sham stimulation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "NeuroPace", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 100, "start_date": "2022-08-09", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05147571" }, { "nct_id": "NCT06908356", "title": "An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Focal Onset Seizure", "Primary Generalized Epilepsy" ], "interventions": [ { "name": "30mg PRAX-628", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Praxis Precision Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 50, "start_date": "2025-01-10", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Miami Lakes, Florida • Bethesda, Maryland + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Chesterfield", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06908356" }, { "nct_id": "NCT06149663", "title": "Intermediate-Size Expanded Access Protocol (EAP) for LP352", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Dravet Syndrome", "Lennox Gastaut Syndrome", "Developmental and Epileptic Encephalopathies" ], "interventions": [ { "name": "LP352", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Longboard Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 19, "location_summary": "Downey, California • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Downey", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gulf Breeze", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06149663" }, { "nct_id": "NCT03655223", "title": "Early Check: Expanded Screening in Newborns", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Spinal Muscular Atrophy", "Fragile X Syndrome", "Fragile X - Premutation", "Duchenne Muscular Dystrophy", "Hyperinsulinemic Hypoglycemia, Familial 1", "Diabetes Mellitus", "Adrenoleukodystrophy, Neonatal", "Medium-chain Acyl-CoA Dehydrogenase Deficiency", "Very Long Chain Acyl Coa Dehydrogenase Deficiency", "Beta-ketothiolase Deficiency", "Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency", "Primary Hyperoxaluria Type 1", "Congenital Bile Acid Synthesis Defect Type 2", "Pyridoxine-Dependent Epilepsy", "Hereditary Fructose Intolerance", "Hypophosphatasia", "Hyperargininemia", "Mucopolysaccharidosis Type 6", "Argininosuccinic Aciduria", "Citrullinemia, Type I", "Wilson Disease", "Maple Syrup Urine Disease, Type 1A", "Maple Syrup Urine Disease, Type 1B", "Biotinidase Deficiency", "Neonatal Severe Primary Hyperparathyroidism", "Intrinsic Factor Deficiency", "Usher Syndrome Type 1D/F Digenic (Diagnosis)", "Cystic Fibrosis", "Stickler Syndrome Type 2", "Stickler Syndrome Type 1", "Alport Syndrome, Autosomal Recessive", "Alport Syndrome, X-Linked", "Carbamoyl Phosphate Synthetase I Deficiency Disease", "Carnitine Palmitoyl Transferase 1A Deficiency", "Carnitine Palmitoyltransferase II Deficiency", "Cystinosis", "Chronic Granulomatous Disease", "Cerebrotendinous Xanthomatoses", "Maple Syrup Urine Disease, Type 2", "Severe Combined Immunodeficiency Due to DCLRE1C Deficiency", "Thyroid Dyshormonogenesis 6", "Thyroid Dyshormonogenesis 5", "Supravalvar Aortic Stenosis", "Factor X Deficiency", "Hemophilia A", "Hemophilia B", "Tyrosinemia, Type I", "Fructose 1,6 Bisphosphatase Deficiency", "Glycogen Storage Disease Type I", "G6PD Deficiency", "Glycogen Storage Disease II", "Galactokinase Deficiency", "Mucopolysaccharidosis Type IV A", "Galactosemias", "Guanidinoacetate Methyltransferase Deficiency", "Agat Deficiency", "Glutaryl-CoA Dehydrogenase Deficiency", "Gtp Cyclohydrolase I Deficiency", "Hyperinsulinism-Hyperammonemia Syndrome", "Primary Hyperoxaluria Type 2", "3-Hydroxyacyl-CoA Dehydrogenase Deficiency", "Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency", "Mitochondrial Trifunctional Protein Deficiency", "Sickle Cell Disease", "Beta-Thalassemia", "Holocarboxylase Synthetase Deficiency", "3-Hydroxy-3-Methylglutaric Aciduria", "Primary Hyperoxaluria Type 3", "Hermansky-Pudlak Syndrome 1", "Hermansky-Pudlak Syndrome 4", "Apparent Mineralocorticoid Excess", "HSDB", "CBAS1", "Mucopolysaccharidosis Type 2", "Mucopolysaccharidosis Type 1", "Severe Combined Immunodeficiency, X Linked", "Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency", "Diabetes Mellitus, Permanent Neonatal", "Isovaleric Acidemia", "Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder)", "Jervell and Lange-Nielsen Syndrome 2", "Hyperinsulinemic Hypoglycemia, Familial, 2", "Diabetes Mellitus, Permanent Neonatal, With Neurologic Features", "Jervell and Lange-Nielsen Syndrome 1", "Lysosomal Acid Lipase Deficiency", "CblF", "3-Methylcrotonyl CoA Carboxylase 1 Deficiency", "3-Methylcrotonyl CoA Carboxylase 2 Deficiency", "Waardenburg Syndrome Type 2A", "Methylmalonic Aciduria cblA Type", "Methylmalonic Aciduria cblB Type", "Methylmalonic Aciduria and Homocystinuria Type cblC", "MAHCD", "Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency", "Congenital Disorder of Glycosylation Type 1B", "Mthfr Deficiency", "Methylcobalamin Deficiency Type Cbl G (Disorder)", "Methylcobalamin Deficiency Type cblE", "Usher Syndrome, Type 1B", "N-acetylglutamate Synthase Deficiency", "Ornithine Transcarbamylase Deficiency", "Phenylketonurias", "Waardenburg Syndrome Type 1", "Congenital Hypothyroidism", "Propionic Acidemia", "Usher Syndrome, Type 1F", "Pancreatic Agenesis 1", "Hereditary Hypophosphatemic Rickets", "Glycogen Storage Disease IXB", "Glycogen Storage Disease IXC", "MOWS", "Epilepsy, Early-Onset, Vitamin B6-Dependent", "Pyridoxal Phosphate-Responsive Seizures", "Pituitary Hormone Deficiency, Combined, 1", "Ptsd", "Dihydropteridine Reductase Deficiency", "Severe Combined Immunodeficiency Due to RAG1 Deficiency", "Severe Combined Immunodeficiency Due to RAG2 Deficiency", "Retinoblastoma", "Multiple Endocrine Neoplasia Type 2B", "Pseudohypoaldosteronism, Type I", "Liddle Syndrome", "Biotin-Responsive Basal Ganglia Disease", "SCD", "DIAR1", "GSD1C", "Acrodermatitis Enteropathica", "Thyroid Dyshormonogenesis 1", "Riboflavin Transporter Deficiency", "Waardenburg Syndrome, Type 2E", "SRD", "Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency", "Barth Syndrome", "Adrenocorticotropic Hormone Deficiency", "Transcobalamin II Deficiency", "Thyroid Dyshormonogenesis 3", "Segawa Syndrome, Autosomal Recessive", "Autosomal Recessive Nonsyndromic Hearing Loss", "Thyroid Dyshormonogenesis 2A", "Congenital Isolated Thyroid Stimulating Hormone Deficiency", "Hypothyroidism Due to TSH Receptor Mutations", "Usher Syndrome Type 1C", "Usher Syndrome Type 1G (Diagnosis)", "Von Willebrand Disease, Type 3", "Combined Immunodeficiency Due to ZAP70 Deficiency", "Adenine Phosphoribosyltransferase Deficiency", "Metachromatic Leukodystrophy", "Canavan Disease", "Menkes Disease", "Carbonic Anhydrase VA Deficiency", "Developmental and Epileptic Encephalopathy 2", "17 Alpha-Hydroxylase Deficiency", "Smith-Lemli-Opitz Syndrome", "Krabbe Disease", "Glutathione Synthetase Deficiency", "Mucopolysaccharidosis Type 7", "Rett Syndrome", "Molybdenum Cofactor Deficiency, Type A", "Niemann-Pick Disease, Type C1", "Niemann-Pick Disease Type C2", "Ornithine Aminotransferase Deficiency", "3-Phosphoglycerate Dehydrogenase Deficiency", "Leber Congenital Amaurosis 2", "Dravet Syndrome", "Mucopolysaccharidosis Type 3 A", "Ornithine Translocase Deficiency", "Carnitine-acylcarnitine Translocase Deficiency", "Glucose Transporter Type 1 Deficiency Syndrome", "Creatine Transporter Deficiency", "Niemann-Pick Disease Type A", "Pitt Hopkins Syndrome", "Tuberous Sclerosis 1", "Tuberous Sclerosis 2", "Ataxia With Isolated Vitamin E Deficiency", "Angelman Syndrome", "Prader-Willi Syndrome", "Homocystinuria", "Permanent Neonatal Diabetes Mellitus", "Transient Neonatal Diabetes Mellitus", "Factor VII Deficiency", "Glycogen Storage Disease Type IXA1", "Glycogen Storage Disease, Type IXA2", "Glycogen Storage Disease IC", "Glycogen Storage Disease Type IB", "Central Hypoventilation Syndrome With or Without Hirschsprung Disease" ], "interventions": [ { "name": "Confirmatory Testing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "RTI International", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Day", "maximum_age": "31 Days", "sex": "ALL", "summary": "1 Day to 31 Days" }, "enrollment_count": 30000, "start_date": "2018-10-15", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-05-22T05:39:04.342Z", "location_count": 1, "location_summary": "Research Triangle Park, North Carolina", "locations": [ { "city": "Research Triangle Park", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03655223" } ] }